CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

Strategies that enhance the function of T cells are critical for immunotherapy. One negative regulator of T-cell activity is ligand PD-L1, which is expressed on dentritic cells (DCs) or some tumor cells, and functions through binding of programmed death-1 (PD-1) receptor on activated T cells. Here w...

Full description

Bibliographic Details
Main Authors: Su, Shu, Hu, Bian, Shao, Jie, Shen, Bin, Du, Juan, Du, Yinan, Zhou, Jiankui, Yu, Lixia, Zhang, Lianru, Chen, Fangjun, Sha, Huizi, Cheng, Lei, Meng, Fanyan, Zou, Zhengyun, Huang, Xingxu, Liu, Baorui
Format: Online
Language:English
Published: Nature Publishing Group 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730182/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730182/

Similar Items